New research validates patient-reported improvements with INGREZZA in treating tardive dyskinesia.

Neurocrine Biosciences published research in The Journal of Clinical Psychiatry confirming that the Tardive Dyskinesia Impact Scale (TDIS) effectively measures patient-reported improvements during treatment with INGREZZA (valbenazine). The study defines a meaningful improvement threshold, showing that INGREZZA reduces the physical, social, and emotional burdens of tardive dyskinesia, a movement disorder caused by certain psychiatric medications. This supports previous clinical trial findings and highlights the importance of patient perspectives in assessing treatment benefits. INGREZZA remains a key treatment option for adults with tardive dyskinesia, offering flexible dosing and a sprinkle formulation for easier use.